英诺特业绩快报：2025年度净利润1.46亿元，同比下降40.84%

Core Viewpoint - In 2025, the company Innotec (688253.SH) reported a significant decline in both revenue and net profit, primarily due to regulatory impacts and increased competition in the in vitro diagnostics industry [1] Financial Performance - The company achieved total operating revenue of 422 million yuan, representing a year-on-year decrease of 32.08% [1] - The net profit attributable to the parent company was 146 million yuan, reflecting a year-on-year decline of 40.84% [1] Industry Context - The in vitro diagnostics industry faced challenges from healthcare regulatory policies and tax policies, which negatively impacted the company's performance in 2025 [1] - Increased competition in specific testing areas, such as respiratory and digestive pathogens, further pressured the company's overall performance [1]